Harvard Bioscience Inc (HBIO)
Harvard Bioscience Inc (HBIO) is a global developer and manufacturer of biomedical research and clinical products. The company offers equipment and tools used in life sciences research, including instruments for cell analysis, laboratory automation, and tissue culture. Harvard Bioscience serves academic, government, and industry customers by supporting advances in biomedical research and drug development.
Company News
Harvard Bioscience reported Q2 2025 GAAP revenue of $20.5 million, exceeding analyst expectations by 9.3% despite an 11.3% year-over-year decline. The company showed improved operational cash flow and continued focus on new product development in biomedical research technologies.
Harvard Bioscience announced the appointment of John Duke to its board of directors and the retirement of Thomas Loewald. The company also reported its first quarter 2025 financial results.
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock...